As quoted by DIA
” Measure.McClatchy (6/27, Rudansky) reports that the Senate has approved a measure “that will quicken the approval process for drugs intended to treat patients with rare diseases.” The provision, which was drafted by Sen. Kay Hagan, “passed the Senate as part of a wider bill that updates and reworks the user fees paid by drug companies that are seeking Food and Drug Administration approval for their products.” Hagan said it is”significant for patients suffering from diseases that don’t have adequate treatment options or might have no treatment options at all.”